Invivyd (IVVD) News Today

Company: Invivyd, Inc. (NASDAQ:IVVD)

Invivyd shares are trading lower amid dilution concerns from a new stock offering, a wave of downward earnings revisions from HC Wainwright and fresh insider selling. Offsetting these pressures are reports of robust revenue growth and continued analyst Buy ratings.

• Positive Sentiment: Social media discussions highlighted over 400% year-over-year revenue growth in Q2 and optimism around the antibody pipeline, with analysts reaffirming Buy ratings. Q2 2025 Earnings and Insider Selling
• Neutral Sentiment: Invivyd initiated an underwritten public offering of common stock under its shelf registration to fund clinical trials and other research programs. Proposed Public Offering
• Negative Sentiment: Priced a $50 million public offering at $0.52 per share (plus pre-funded warrants), increasing share count and diluting existing equity. Pricing of $50M Offering
• Negative Sentiment: Shares dipped after the company priced the $50 million capital raise via securities offering. MSN: Capital Raise
• Negative Sentiment: HC Wainwright cut its FY 2028 EPS forecast to $0.13 (from $0.18) and lowered multiple earnings estimates for FY 2025–FY 2027. HC Wainwright Earnings Revisions
• Negative Sentiment: Insider Robert Allen III sold 18,512 shares at an average price of $0.65, reducing his stake and raising questions about insider confidence. Insider Selling Alert